Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Verus International Inc (VRUS)

Verus International Inc (VRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Verus International Inc

www.pharmasset.com

Description:

Pharmasset, Inc. was incorporated under the laws of Delaware on June 8, 2004. It is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. The Company's primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. It currently has three clinical-stage product candidates, two of which it is developing ourselves and one of which it is developing with a strategic partner. It is also advancing a series of preclinical candidates in preparation for clinical development. The Company's three clinical stage product candidates are: RG7128, an HCV cytosine nucleoside polymerase inhibitor it is developing through a strategic collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc; PSI-7977, an HCV uracil nucleotide analog polymerase inhibitor that is in a 12-week Phase 2b study in combination with SOC in patients with HCV genotypes 1, 2 or 3; and PSI-938, an HCV guanine nucleotide analog polymerase inhibitor that is screening patients for Part 2 of a Phase 1 study with PSI-7977 in patients with HCV genotype 1. Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture and marketing of pharmaceutical products and in research and development activities.

Key Statistics

Overview:

Annual Sales, $ 890 K
Annual Net Income, $ -91,180 K
Short Volume Ratio 1.00

Growth:

1-Year Return 0.00%
3-Year Return 0.00%
5-Year Return 0.00%

Per-Share Information:

Next Earnings Date 02/06/12
EPS Growth vs. Prev Qtr -10.00%
EPS Growth vs. Prev Year -11.86%
Dividend Payout Ratio 0.00%

VRUS Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 0.00
Price/Earnings to Growth 0.00
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow 0.00
Price/Book 66.95
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar